Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Context Therapeutics (NASDAQ:CNTX) posted its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03, FiscalAI reports.

Context Therapeutics Stock Up 15.6%

Shares of CNTX opened at $0.22 on Thursday. The business’s 50-day moving average price is $0.29 and its 200-day moving average price is $1.39. Context Therapeutics has a twelve month low of $0.18 and a twelve month high of $3.62. The stock has a market cap of $19.86 million, a PE ratio of -0.47 and a beta of 1.77.

Analysts Set New Price Targets

Several research firms recently commented on CNTX. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Zacks Research raised shares of Context Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday. Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.40.

Context Therapeutics Company Profile

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.